HR Licensing RNA 
The Pharma Data
NOVEMBER 17, 2021
Food and Drug Administration (FDA) includes clinical data from the Phase2/3 EPIC-HR ( Evaluation of Protease Inhibition for COVID-19 in High- Threat Cases) interim analysis. PF-07321332 inhibits viral replication at a stage known as proteolysis, which occurs before viral RNA replication. This submission to theU.S. FDA in October 2021.
The Pharma Data
NOVEMBER 19, 2021
.” PF-07321332 is designed to block the exertion of the SARS-CoV-2-3CL protease, an enzyme that the coronavirus needs to replicate, at a stage known as proteolysis-which occurs before viral RNA replication.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pfizer
JANUARY 27, 2023
Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication. In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. No dosage adjustment is needed in patients with mild renal impairment.
Pfizer
AUGUST 15, 2022
Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication. In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. PAXLOVID is not authorized for use for longer than 5 consecutive days. anti-infectives).
Pfizer
DECEMBER 20, 2022
Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication. PAXLOVID may only be prescribed for an individual patient by physicians, advanced practice registered nurses, and physician assistants that are licensed or authorized under state law to prescribe drugs.
Pfizer
DECEMBER 13, 2022
Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication. PAXLOVID may only be prescribed for an individual patient by physicians, advanced practice registered nurses, and physician assistants that are licensed or authorized under state law to prescribe drugs.
Pfizer
NOVEMBER 23, 2022
Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication. PAXLOVID may be prescribed for an individual patient by physicians, advanced practice registered nurses, and physician assistants that are licensed or authorized under state law to prescribe drugs. .
Expert insights. Personalized for you.
52 
Let's personalize your content